Methods of treating cancer by targeting tumor-associated macrophages
US-2024415921-A1 · Dec 19, 2024 · US
Composition for treating apoplexy through nasal administration
US10772827B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10772827-B2 |
| Application number | US-201615775813-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 14, 2016 |
| Priority date | Nov 13, 2015 |
| Publication date | Sep 15, 2020 |
| Grant date | Sep 15, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an ischemic stroke, comprising intranasally administering a pharmaceutically effective amount of a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a linear FAS targeting peptide (FTP) having the amino acid sequence of SEQ ID NO: 1 and wherein the intranasal administration is performed while a subject is in a sleeping, anesthetized, or unconscious state. 2. The method of claim 1 , wherein the pharmaceutical composition is contained in an injection device comprising a container configured to contain the pharmaceutical composition to be intranasally administered.
Assignees
Inventors
Classifications
- A61K38/08Primary
Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
- A61K9/0043Primary
Nose · CPC title
of the injector type · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10772827B2 cover?
- The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated.
- Who is the assignee on this patent?
- Univ Hanyang Ind Univ Coop Found
- What technology area does this patent fall under?
- Primary CPC classification A61K38/08. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).